Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations
Our studies indicate a synergistic benefit from combined PARPi and AURKAi in mutant and wild-type BRCA EOC tumors.
Authors
- Linda J. Paradiso
- Soumya M. Turaga (ORCID: https://orcid.org/0000-0002-1933-2764)
- Masha G. Savelieff (ORCID: https://orcid.org/0000-0001-5575-2494)
- Harsh B. Pathak (ORCID: https://orcid.org/0000-0003-4034-0520)
- Andrew K. Godwin (ORCID: https://orcid.org/0000-0002-3987-9580)
- Rajni V. Puri (ORCID: https://orcid.org/0000-0002-0570-7350)
- Arnab Ghosh (ORCID: https://orcid.org/0000-0003-0355-7763)
- Stacey L. Hembruff (ORCID: https://orcid.org/0009-0006-3224-4773)
- Thomas J. Myers
- Ao Li (ORCID: https://orcid.org/0009-0004-7185-3681)
Institutions
- University of North Dakota (US)
- The University of Kansas Cancer Center (US)
- Rajiv Gandhi University (IN)
- Innopharma Education (IE)
- University of Kansas Medical Center (US)
- MathWorks (United States) (US)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1007/s00432-025-06152-7
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Honorable Tina Brozman Foundation
- National Cancer Institute